EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Bariatric Surgery in the Era of GLP1RA: A Narrative Review

Mathula Muhundan, Satya Dash iD

Advances in Therapy · 2026-03 · 43 (3) · 1082-1097

DOI: 10.1007/s12325-026-03494-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, online erschienen am 02.02.2026. Verfasst von Mathula Muhundan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Bariatric Surgery, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of obesity continues to rise, with notable increase in stage III obesity in North America. The accumulation of excess adipose tissue can impair health with cardiovascular disease being the leading cause for increased mortality in people with obesity. The chronicity of the condition makes sustainable weight loss and improved health difficult for many with lifestyle changes alone, often necessitating the need for pharmacotherapy and bariatric surgery. Bariatric surgery remains the most efficacious treatment for obesity, despite improved pharmacotherapies. However, its low acceptability and accessibility render it an underutilized treatment. Meanwhile, the use of obesity pharmacotherapy, especially glucagon-like peptide 1 receptor agonists (GLP1RA) has become widespread with significant weight loss and improved health outcomes in randomised control trials. The real-world effectiveness of GLP1RA is hindered by issues including cost and tolerability. This narrative review discusses strategies to improve the effectiveness of pharmacotherapy and bariatric surgery and posits that bariatric surgery will continue to play an important role in obesity treatment in the GLP1RA era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsObesityAnti-Obesity AgentsHumansWeight LossSemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

Bariatric surgeryCagrilintide-semaglutide (cagri-sema)GLP-1 receptor agonistsObesityPharmacotherapySemaglutideTirzepatideWeight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsSemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Faculty of Medicine, Memorial University of Newfoundland, St John's, NL, Canada.
  • Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada. satya.dash@uhn.ca.

ORCID-Profile: Satya Dash

Zitieren

APA

Muhundan, M., & Dash, S. (2026). Bariatric Surgery in the Era of GLP1RA: A Narrative Review. Advances in Therapy, 43(3), 1082-1097. https://doi.org/10.1007/s12325-026-03494-7

Vancouver

Muhundan M, Dash S. Bariatric Surgery in the Era of GLP1RA: A Narrative Review. Advances in Therapy. 2026;43(3):1082-1097. doi:10.1007/s12325-026-03494-7

BibTeX
@article{Muhundan2026,
  author = {Muhundan, Mathula and Dash, Satya},
  title = {Bariatric Surgery in the Era of GLP1RA: A Narrative Review},
  journal = {Advances in Therapy},
  year = {2026},
  volume = {43},
  number = {3},
  pages = {1082--1097},
  doi = {10.1007/s12325-026-03494-7}
}
Kostenlos starten →